Jacobs Bruce N.
SEC CIK 1821074 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | CFO | 322.0K | — | $16.25M | 30 | 2021-09-03 | 2026-06-30 |
Most active insiders at KYMR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Booth Bruce | Dir | — | $226.03M |
| 2 | BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | — | $173.67M |
| 3 | BAKER FELIX | Dir, 10% | $172.50M | — |
| 4 | Mainolfi Nello | CEO, Dir | — | $33.41M |
| 5 | Chadwick Jeremy G | COO | — | $15.60M |
| 6 | Jacobs Bruce N. | CFO | — | $9.96M |
| 7 | Gollob Jared | Chief Medical Off | — | $9.13M |
| 8 | Esposito Pamela | Dir | — | $3.05M |
| 9 | Goodman Noah | Chief Business Off | — | $2.22M |
| 10 | Ridloff Elena | Dir | — | $1.29M |
Transactions 30
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-02 18:30 | 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $5.33 | +61.4K | 322.0K | +24% | +$327.1K |
| DMT | 2026-07-02 18:30 | 2026-06-30 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $114.96 | -77.1K | 244.9K | -24% | -$8.86M |
| D | 2026-06-03 07:30 | 2026-06-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +12.7K | 260.2K | +5% | +$26.3K |
| D | 2026-05-19 07:30 | 2026-05-18 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +15.0K | 247.6K | +6% | +$31.2K |
| DM | 2026-03-04 | 2026-03-02+ | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale | $87.50 | -12.5K | 234.5K | -5% | -$1.09M |
| D | 2026-03-04 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +17.6K | 245.1K | +8% | $0 |
| DT | 2025-09-17 | 2025-09-17 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +79.2K | 306.6K | +35% | +$164.8K |
| DT | 2025-09-17 | 2025-09-17 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $50.00 | -79.2K | 227.4K | -26% | -$3.96M |
| D | 2025-04-01 | 2025-03-31 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +25.0K | 226.9K | +12% | +$52.0K |
| D | 2025-03-03 | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +30.0K | 208.9K | +17% | $0 |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale | $30.45 | -7,035 | 201.9K | -3% | -$214.2K |
| D | 2025-01-13 | 2025-01-10 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 178.9K | +6% | +$20.8K |
| D | 2024-06-28 | 2024-06-27 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +25.0K | 168.6K | +17% | +$52.0K |
| DM | 2024-03-04 | 2024-03-04 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale | $41.85 | -3,934 | 143.9K | -3% | -$164.7K |
| D | 2024-03-04 | 2024-03-01 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +31.2K | 146.3K | +27% | $0 |
| D | 2023-06-02 | 2023-06-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 115.0K | +10% | +$20.8K |
| D | 2023-03-03 | 2023-03-01 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +23.8K | 105.9K | +29% | $0 |
| DM | 2023-03-03 | 2023-03-02 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale | $31.00 | -1,370 | 104.6K | -1% | -$42.5K |
| D | 2022-10-24 | 2022-10-21 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 81.3K | +14% | +$20.8K |
| D | 2022-10-17 | 2022-10-17 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 71.3K | +16% | +$20.8K |
| D | 2022-05-03 | 2022-05-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +20.0K | 60.8K | +49% | +$41.6K |
| D | 2022-03-03 | 2022-03-01 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | A - Grant | $0.00 | +13.3K | 40.8K | +48% | $0 |
| DM | 2022-01-14 | 2022-01-12 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $51.84 | -15.0K | 26.1K | -37% | -$777.7K |
| D | 2022-01-14 | 2022-01-12 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +15.0K | 32.5K | +86% | +$31.2K |
| D | 2022-01-14 | 2022-01-14 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 27.5K | +57% | +$20.8K |
| D | 2021-12-03 | 2021-12-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 27.5K | +57% | +$20.8K |
| DM | 2021-12-03 | 2021-12-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $53.56 | -10.0K | 19.8K | -34% | -$535.6K |
| D | 2021-11-23 | 2021-11-23 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | +10.0K | 17.3K | +138% | +$20.8K |
| DM | 2021-09-03 | 2021-09-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $60.12 | -10.0K | 7,256 | -58% | -$601.2K |
| D | 2021-09-03 | 2021-09-03 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | -10.0K | 17.3K | -37% | -$20.8K |
Purchase Sale Sale after option exercise All abbreviations